SELECT
» Biotechnology facts and figures
» Drugs in development
» Key Technologies
DISEASES
» Anemia (2005)
» Breast Cancer (2007)
» Cardiovascular Diseases (2007)
» Diabetes (2005)
» Growth Hormone Deficiency (2005)
» Haemophilia (2005)
» Hepatitis B (2005)
» Inflammatory Bowel Disease (2007)
» Lymphomas (2005)
» Multiple Sclerosis (2005)
» Rheumatoid Arthritis and other Inflammatory Rheumatism (2007)
Biotechnology for
Anemia (2005)
<table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">The disease</span><br> <span class="rteColumn">In general, severe anaemia is the result of a serious disease or of its treatment, such as chronic renal insufficiency (caused by diabetes or high blood pressure) or certain types of cancer treated with chemotherapy. It is characterized by a lack of red corpuscles and is therefore due to a deficiency in the amount of oxygen carried to the body tissues. </span> <a href="more.php?diseaseid=19&bloc=1" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">How many people are affected ?</span><br> The number of cases of chronic renal insufficiency in France is approximately 30,000, and 300,000 in the United States. The diseases which cause renal insufficiency, such as diabetes and high blood pressure are the scourge of developed countries and are on the increase. It is generally considered that 50 to 60% of cancer patients treated by chemotherapy will develop severe anaemia that will need to be treated (i.e. approximately 200,000 people in France). <a href="more.php?diseaseid=19&bloc=2" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">How many people die from the disease?</span><br> Currently updated... <a href="more.php?diseaseid=19&bloc=3" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">Living with the disease</span><br> The symptoms of anaemia – headaches, dizziness, shortness of breath and cardiac disorders – are to be added to the already major symptoms of the main disease and considerably worsen the state of the patient, accounting for a significant part in the mortality rate. <a href="more.php?diseaseid=19&bloc=4" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> <tr> <td><span class="diseaseSubTitle">Treatment <font color='#FFFFFF' size=-2>Témoignage patient de </font> </span></td> </tr> <tr> <td><span class="diseaseText"><img src="../images/pix.gif" width="1" height="10"></span></td> </tr> </table> <table border="0" cellspacing="0" cellpadding="5"> <tr> <td valign="top" bgcolor="#B9E3FF"> <span class="diseaseSubTitle2">Traditional approach</span><br> Before the late 1980’s, severe anaemia was treated by blood transfusion with the principal risk being that of viral infection (AIDS and Hepatitis B and C). <a href="more.php?diseaseid=19&bloc=5" class="lienBleu">More</a></td> <td> </td> <td valign="top" bgcolor="#B9E3FF"> <span class="diseaseSubTitle2">Biotech revolutions</span><br> Since 1989, a protein naturally synthesized by the kidney, erythropoietin, has been produced industrially using the techniques of biotechnology. This protein stimulates production of red corpuscles. A simple injection once or several times a week can thus correct severe anaemia without significant side effects. <a href="more.php?diseaseid=19&bloc=6" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/spacer.gif" width="227" height="1"></td> <td><img src="../images/spacer.gif" width="1" height="1"></td> <td><img src="../images/spacer.gif" width="227" height="1"></td> </tr> <tr bgcolor="#B9E3FF"> <td colspan="3"> <span class="diseaseSubTitle2">Drugs currently available</span><br> Three recombinant proteins have been developed: epoetin alpha, epoetin beta and darbepoetin alpha, the latter being a sustained release product requiring less injections that the preceding two. These proteins are then introduced into medical preparations sold by a number of different pharmaceutical companies. <a href="more.php?diseaseid=19&bloc=7" class="lienBleu">More</a></td> </tr> <tr> <td colspan="3"><img src="../images/pix.gif" width="1" height="5"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">Number of patients treated</span><br> The target population for erythropoietin in France is estimated to be approximately 200,000 patients. Globally, the number of patients to be treated is estimated to be more than 1.3 million per annum. Since this drug has been on the market, the impact on patient quality of life and on mortality has been very significant. <a href="more.php?diseaseid=19&bloc=8" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">Future</span><br> The expected developments in the treatment of severe anaemia will essentially be the reduction in the number of injections (currently at best once a week). <a href="more.php?diseaseid=19&bloc=9" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table> <table width="485" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top"> <span class="diseaseSubTitle">Costs to society</span><br> The market for EPO is considerable. It is estimated to be around ten billion Euros per annum and has been constantly on the increase for a number of years. Given the increase in illnesses directly responsible for severe anaemias (in particular diabetes and high blood pressure), this market should continue to grow very rapidly. <a href="more.php?diseaseid=19&bloc=10" class="lienBleu">More</a></td> </tr> <tr> <td><img src="../images/pix.gif" width="1" height="15"></td> </tr> </table>
